Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 35403841

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
N Engl J Med
Publication date
2022 May 26
First author
Forde PM

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    N Engl J Med. 2022 May 26;386(21):2050-2051. doi: 10.1056/NEJMe2203330.
    note
    Source null
    related pmid
    35403840
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2022 Aug;19(8):497-498. doi: 10.1038/s41571-022-00647-9.
    note
    Source null
    related pmid
    35585121
    relationship
    Comment in
  3. citation
    Cancer Cell. 2022 Jun 13;40(6):603-605. doi: 10.1016/j.ccell.2022.05.010.
    note
    Source null
    related pmid
    35660136
    relationship
    Comment in
  4. citation
    Cell Rep Med. 2022 Jul 19;3(7):100691. doi: 10.1016/j.xcrm.2022.100691.
    note
    Source null
    related pmid
    35858590
    relationship
    Comment in
  5. citation
    N Engl J Med. 2022 Aug 11;387(6):571. doi: 10.1056/NEJMc2208133.
    note
    Source null
    related pmid
    35947717
    relationship
    Comment in
  6. citation
    N Engl J Med. 2022 Aug 11;387(6):571-572. doi: 10.1056/NEJMc2208133.
    note
    Source null
    related pmid
    35947718
    relationship
    Comment in

Authors and identifiers

  1. name
    Forde PM
    type
    Author
  2. name
    Spicer J
    type
    Author
  3. name
    Lu S
    type
    Author
  4. name
    Provencio M
    type
    Author
  5. name
    Mitsudomi T
    type
    Author
  6. name
    Awad MM
    type
    Author
  7. name
    Felip E
    type
    Author
  8. name
    Broderick SR
    type
    Author
  9. name
    Brahmer JR
    type
    Author
  10. name
    Swanson SJ
    type
    Author
  11. name
    Kerr K
    type
    Author
  12. name
    Wang C
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Forde PM
    type
    Author
  2. name
    Spicer J
    type
    Author
  3. name
    Lu S
    type
    Author
  4. name
    Provencio M
    type
    Author
  5. name
    Mitsudomi T
    type
    Author
  6. name
    Awad MM
    type
    Author
  7. name
    Felip E
    type
    Author
  8. name
    Broderick SR
    type
    Author
  9. name
    Brahmer JR
    type
    Author
  10. name
    Swanson SJ
    type
    Author
  11. name
    Kerr K
    type
    Author
  12. name
    Wang C
    type
    Author
bibliography ids
  1. nci-bib-5dede692e82c3399c4e021c4
book metadata
content sha256
9646e96f8a64f9391d4ecce6e40aecc1bc74345bdfdbe8541d4b9d4411ffb3c0
document type
citation
dois
  1. 10.1056/NEJMoa2202170
electronic publication date
display
2022 Apr 11
precision
day
year
2022
evidence scope
bibliographic_metadata_only
id
pubmed:35403841
immutable id
pubmed:35403841@9646e96f8a64f9391d4ecce6e40aecc1bc74345bdfdbe8541d4b9d4411ffb3c0
journal
abbreviation
N Engl J Med
issn electronic
1533-4406
issn print
0028-4793
issue
21
name
The New England journal of medicine
nlm unique id
0255562
pages
1973-1985
volume
386
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    N Engl J Med. 2022 May 26;386(21):2050-2051. doi: 10.1056/NEJMe2203330.
    note
    Source null
    related pmid
    35403840
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2022 Aug;19(8):497-498. doi: 10.1038/s41571-022-00647-9.
    note
    Source null
    related pmid
    35585121
    relationship
    Comment in
  3. citation
    Cancer Cell. 2022 Jun 13;40(6):603-605. doi: 10.1016/j.ccell.2022.05.010.
    note
    Source null
    related pmid
    35660136
    relationship
    Comment in
  4. citation
    Cell Rep Med. 2022 Jul 19;3(7):100691. doi: 10.1016/j.xcrm.2022.100691.
    note
    Source null
    related pmid
    35858590
    relationship
    Comment in
  5. citation
    N Engl J Med. 2022 Aug 11;387(6):571. doi: 10.1056/NEJMc2208133.
    note
    Source null
    related pmid
    35947717
    relationship
    Comment in
  6. citation
    N Engl J Med. 2022 Aug 11;387(6):571-572. doi: 10.1056/NEJMc2208133.
    note
    Source null
    related pmid
    35947718
    relationship
    Comment in
outcomes validated
false
pmid
35403841
provenance
batch id
3f4d1914d2afe41e9e70
provider
NCBI PubMed ESummary
record sha256
82377b92f3d4e6585850aa2b61f62f85efc3dab1483f8279cdbb239a270e64ae
response sha256
0ceeb248a527e54c6f72dd28d20f7abec08a973fe2e10de00bede4895add09e7
retrieved at
2026-09-09T23:48:06.522634+00:00
publication date
display
2022 May 26
precision
day
year
2022
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Randomized Controlled Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/35403841/
title
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.

Preserved source evidence · Not medical advice